First, one individual saying " he believes the results will be delayed" certainly does not make it so.
His closing remarks about " selling this pos" cements his motives.
Recently, I posted a fair & very inclusive review of Onc. Within it they gave various scenarios & view points of comparables.
using their mid point target of mid $8ps etc etc.
That said, why would anyone sell Onc " now".
The SP is near historical lows. Meaning downside very limited.
While at the same time , the upside is " potentially " beyond any prediction.
the lead/ jones & gable report with its mid $8 target.
Is using a relatively low discount. That discount rate on phase 3 partnership easily doubles the prediction to $16 PS.
They re using forward income projections, to come up with present day valuations.
the further out the income & the more uncertainty, the greater the target is discounted.
Lin business it's called " doubt = discount "
Will they delay results ..again? I have no idea of predicting that. Since the results PFS, is a time based outcome, I doubt it.
Time is a constant, so far we have not been able to change.
so, enjoy your week.
I know it is a very hard concept for some. The trading SP, has zero to do with future prtership or buyout opportunities.
both of those come from the science & it's potential value to the aquiring pharma.
RBC has said from day 1, that Pelareorep has a market potential of $5billion/year. ....once approved etc.
That being for MBc only. Not counting any if the recent G.I. Cancer opportunities.
THAT , is what a pharma partner looks at. The trading SP is 100% irrelevant to them.
The income potential is 100% what they look at.
Coming a full circle : ASCO is weeks away.
management has repeatedly said they expect to release good results then.
Absouloutly a high risk investment. Most junior biotechs are.
The down side? I think even in a fire sale the company is worth more than it is trading at, just for tax loss accumulation.
The upside? Pick a number.